Chris J. Powell
Dr Powell is Vice President of Translational Medicine and Comparative Pathobiology at GlaxoSmithKline Pharmaceuticals, with responsibility for experimental studies on the safety and efficacy of new medicines. Previously, he worked in the UK biopharmaceutical industry and was Reader in Pharmaceutical and Chemical Safety at St Bartholomew’s Hospital Medical College, University of London, where he led a group researching mechanisms of hepatotoxicity and non-genotoxic carcinogenicity. Chris trained in biochemistry, pharmacology and histopathology at the University of Wales, Imperial College London, the University of Surrey and he is a Fellow of the Royal College of Pathologists and the British Toxicology Society.
Dr Powell’s research interests include: mechanisms of toxicity and their application to human risk evaluation, non-genotoxic mechanisms of chemical carcinogenicity and the human translational relevance of experimental safety studies. He is a member of the Royal Society of Biology, the Society of Toxicology, the UK Pathology Society and is a regular speaker at scientific meetings.
Dr Powell has served on several Scientific Advisory Committees for the UK/EU Government and for the World Health Organisation. He is currently a member of the UK Dept Health Advisory Committee on Carcinogenicity, the Grant Review Panel for the MRC Integrated Toxicology Training Programme, the Strategic Governing Group on Translational Safety for the European Union’s Innovative Medicines Initiative, Chair of the British Pharmaceutical Industry Association Committee on Experimental Safety and Vice President of the British Toxicology Society.